The company made this announcement after trading hours on Friday, 13 June 2008.

Meanwhile, the BSE Sensex was up 311.65 points, or 2.05%, to 15,501.27, on positive cues from global markets. US stocks closed higher on Friday, 13 June 2008, helped by a government report that showed underlying price pressures rose moderately in May 2008, easing fears that inflation would force a near-term rise in interest rates.

On BSE, 898 shares were traded in the counter. The scrip had an average daily volume of 17,614 shares in the past one quarter.

The stock hit a high of Rs 154.25 and a low of Rs 152.25 so far during the day. The stock had a 52-week high of Rs 276.80 on 18 June 2007 and a 52-week low of Rs 116.60 on 24 March 2008.

The small-cap company had outperformed the market over the past one month till 13 June 2008, declining 0.43% compared to the Sensex’s decline of 12.47%. It had also outperformed the market in the past one quarter, gaining 16.51% compared to Sensex’s decline of 3.62%.

The company has an equity capital of Rs 18.02 crore. Face value per share is Rs 5.

The current price of Rs 152.30 discounts its Q4 March 2008 annualised EPS of Rs 20.91, by a PE multiple of 7.28.

On 11 June 2008, Unichem Laboratories received final approval from US Food and Administration (USFDA) for zaleplon capsules in 5 and 10-milligram strengths.

Unichem Laboratories’ net profit fell 6% to Rs 18.84 crore on 3.2% increase in net sales to Rs 138.34 crore in Q4 March 2008 over Q4 March 2007.

The company is engaged in manufacturing and marketing pharmaceutical formulations, bulk drugs and drug intermediates.